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Background: Percutaneous mitral valve repair using the transcatheter MitraClip device is a novel therapy recently FDA approved for 
patients with severe degenerative mitral regurgitation (DMR) who are at prohibitive risk for surgery. We herein report the results of an 
ongoing single-center post-market series in the United States.
methods: Patients were screened with transthoracic (TTE) and transesophageal echocardiography (TEE). Between November of 2013 and 
September of 2014, 154 patients presented with severe (4+) DMR. Mitral valve surgery was performed in 110 (71.4%) of these patients. 
A multi-disciplinary heart team deemed 42 (27.2%) patients to be at prohibitive risk for surgery. The MitraClip was deployed under 2- and 
3-dimensional TEE, 3D real-time intracardiac echocardiography, and fluoroscopic guidance.
results: Mean age was 78±9 years and the average STS score was 12.2%. MitraClip deployment was successful in 41/42 patients 
(97.6%); 1 case was unsuccessful due to a very small left atrium. Two clips were deployed in 22 patients (52.3%). There were no vascular 
complications, strokes or procedural deaths. At 30 days, 2 patients died (4.7%), 1 due to respiratory failure at 48 hours and 1 due to a 
stroke at 3 weeks. At 1-month follow-up, 34 patients (80.9%) had Grade 1-2+ MR. Left ventricular ejection fraction was unchanged from 
baseline to 1 month (mean 40% to 39.5% respectively, P=0.80). NYHA class, however, improved significantly following intervention with 
72.7% of patients being NYHA class I/II at 1 month compared to 12.5% at baseline (P=0.0002). Mean BNP levels decreased significantly 
following MitraClip from 1739 pg/ml at baseline to 377.84 pg/ml at 1 month (P=0.02).
conclusion:  In our experience approximately 1 in 3 patients with severe DMR may not be eligible for mitral valve surgery. MitraClip edge-
to-edge repair is feasible in such patients, and successfully reduces the severity of MR while improving NYHA class in the majority. Further 
studies are needed to examine whether these results are durable and associated with improved outcomes.
